255 related articles for article (PubMed ID: 15956209)
1. The molecular basis of ferroportin-linked hemochromatosis.
De Domenico I; Ward DM; Nemeth E; Vaughn MB; Musci G; Ganz T; Kaplan J
Proc Natl Acad Sci U S A; 2005 Jun; 102(25):8955-60. PubMed ID: 15956209
[TBL] [Abstract][Full Text] [Related]
2. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin.
Drakesmith H; Schimanski LM; Ormerod E; Merryweather-Clarke AT; Viprakasit V; Edwards JP; Sweetland E; Bastin JM; Cowley D; Chinthammitr Y; Robson KJ; Townsend AR
Blood; 2005 Aug; 106(3):1092-7. PubMed ID: 15831700
[TBL] [Abstract][Full Text] [Related]
3. The molecular basis of hepcidin-resistant hereditary hemochromatosis.
Fernandes A; Preza GC; Phung Y; De Domenico I; Kaplan J; Ganz T; Nemeth E
Blood; 2009 Jul; 114(2):437-43. PubMed ID: 19383972
[TBL] [Abstract][Full Text] [Related]
4. The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease.
Zohn IE; De Domenico I; Pollock A; Ward DM; Goodman JF; Liang X; Sanchez AJ; Niswander L; Kaplan J
Blood; 2007 May; 109(10):4174-80. PubMed ID: 17289807
[TBL] [Abstract][Full Text] [Related]
5. Non-HFE hepatic iron overload.
Pietrangelo A; Caleffi A; Corradini E
Semin Liver Dis; 2011 Aug; 31(3):302-18. PubMed ID: 21901660
[TBL] [Abstract][Full Text] [Related]
6. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.
Schimanski LM; Drakesmith H; Merryweather-Clarke AT; Viprakasit V; Edwards JP; Sweetland E; Bastin JM; Cowley D; Chinthammitr Y; Robson KJ; Townsend AR
Blood; 2005 May; 105(10):4096-102. PubMed ID: 15692071
[TBL] [Abstract][Full Text] [Related]
7. Evidence for dimerization of ferroportin in a human hepatic cell line using proximity ligation assays.
Rishi G; Secondes ES; Wallace DF; Subramaniam VN
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32301493
[TBL] [Abstract][Full Text] [Related]
8. Evidence for the multimeric structure of ferroportin.
De Domenico I; Ward DM; Musci G; Kaplan J
Blood; 2007 Mar; 109(5):2205-9. PubMed ID: 17077321
[TBL] [Abstract][Full Text] [Related]
9. Human mutation D157G in ferroportin leads to hepcidin-independent binding of Jak2 and ferroportin down-regulation.
De Domenico I; Lo E; Ward DM; Kaplan J
Blood; 2010 Apr; 115(14):2956-9. PubMed ID: 20124516
[TBL] [Abstract][Full Text] [Related]
10. Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor.
Praschberger R; Schranz M; Griffiths WJ; Baumgartner N; Hermann M; Lomas DJ; Pietrangelo A; Cox TM; Vogel W; Zoller H
Biochim Biophys Acta; 2014 Sep; 1842(9):1406-12. PubMed ID: 24859227
[TBL] [Abstract][Full Text] [Related]
11. Iron overload due to mutations in ferroportin.
De Domenico I; Ward DM; Musci G; Kaplan J
Haematologica; 2006 Jan; 91(1):92-5. PubMed ID: 16434376
[TBL] [Abstract][Full Text] [Related]
12. Clinical, pathological, and molecular correlates in ferroportin disease: a study of two novel mutations.
Girelli D; De Domenico I; Bozzini C; Campostrini N; Busti F; Castagna A; Soriani N; Cremonesi L; Ferrari M; Colombari R; McVey Ward D; Kaplan J; Corrocher R
J Hepatol; 2008 Oct; 49(4):664-71. PubMed ID: 18713659
[TBL] [Abstract][Full Text] [Related]
13. Characterization of three novel pathogenic SLC40A1 mutations and genotype/phenotype correlations in 7 Italian families with type 4 hereditary hemochromatosis.
Majore S; Bonaccorsi di Patti MC; Valiante M; Polticelli F; Cortese A; Di Bartolomeo S; De Bernardo C; De Muro M; Faienza F; Radio FC; Grammatico P; Musci G
Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):464-470. PubMed ID: 29154924
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenesis of hereditary hemochromatosis.
Liu J; Pu C; Lang L; Qiao L; Abdullahi MA; Jiang C
Histol Histopathol; 2016 Aug; 31(8):833-40. PubMed ID: 27031690
[TBL] [Abstract][Full Text] [Related]
15. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.
Aschemeyer S; Qiao B; Stefanova D; Valore EV; Sek AC; Ruwe TA; Vieth KR; Jung G; Casu C; Rivella S; Jormakka M; Mackenzie B; Ganz T; Nemeth E
Blood; 2018 Feb; 131(8):899-910. PubMed ID: 29237594
[TBL] [Abstract][Full Text] [Related]
16. Ferroportin diseases: functional studies, a link between genetic and clinical phenotype.
Détivaud L; Island ML; Jouanolle AM; Ropert M; Bardou-Jacquet E; Le Lan C; Mosser A; Leroyer P; Deugnier Y; David V; Brissot P; Loréal O
Hum Mutat; 2013 Nov; 34(11):1529-36. PubMed ID: 23943237
[TBL] [Abstract][Full Text] [Related]
17. Iron uptake from plasma transferrin by a transferrin receptor 2 mutant mouse model of haemochromatosis.
Chua AC; Delima RD; Morgan EH; Herbison CE; Tirnitz-Parker JE; Graham RM; Fleming RE; Britton RS; Bacon BR; Olynyk JK; Trinder D
J Hepatol; 2010 Mar; 52(3):425-31. PubMed ID: 20133002
[TBL] [Abstract][Full Text] [Related]
18. Rare types of genetic hemochromatosis.
Camaschella C; Poggiali E
Acta Haematol; 2009; 122(2-3):140-5. PubMed ID: 19907151
[TBL] [Abstract][Full Text] [Related]
19. Non-HFE haemochromatosis.
Wallace DF; Subramaniam VN
World J Gastroenterol; 2007 Sep; 13(35):4690-8. PubMed ID: 17729390
[TBL] [Abstract][Full Text] [Related]
20. Hepcidin and ferroportin: the new players in iron metabolism.
De Domenico I; Ward DM; Kaplan J
Semin Liver Dis; 2011 Aug; 31(3):272-9. PubMed ID: 21901657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
